-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
MyC primary cancer gene re-ranking in newly diagnosed multiple myeloma (MM) is common, but its prognosis is unclear.
study was designed to assess the effects of MYC rearm on the clinical characteristics, treatment response and survival rates of newly diagnosed MMs.
the study was a retrospective study that included 1,342 patients who were treated at the Mayo Clinic in Rochester, Minnesota, from January 2006 to January 2018, who were diagnosed with cytogenetic tests for fluorescent in-place hybridization, including MYC testing (8q24.1).
MYC re-emerged in 8% of patients and was associated with the co-emergence of elevated beta-2-microglobulin, ≥50% bone marrow plasma cells, IgA MM, and triplets.
-induced chemotherapy was dominated by protease inhibitors (PI), immunomodulation drugs (IMiDs) or PI-IMiD, there was no difference in the total efficiency of patients who carried MYC rearms and did not carry MYC re-platoons.
lifeseed patients with MYC rearms were shorter than those without MYC rearring (5.3 vs. 8.0 years, P.lt;0.001).
multi-factor analysis found that when high-risk cytogenetic abnormalities, ISS period and age≥70 years of age were included in the analysis, MYC re-ranking was associated with an increased risk of death (risk ratio of 1.5, P-0.007).
.
